Armistice Capital LLC Acquires 136,055 Shares of Can-Fite BioPharma Ltd. (NYSE:CANF)

Armistice Capital LLC raised its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period.

Can-Fite BioPharma Stock Performance

CANF stock opened at $2.05 on Friday. Can-Fite BioPharma Ltd. has a one year low of $1.81 and a one year high of $4.69. The firm has a market cap of $7.26 million, a price-to-earnings ratio of -1.15 and a beta of 1.41. The firm has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $2.49.

Analyst Ratings Changes

Several equities analysts recently issued reports on CANF shares. EF Hutton Acquisition Co. I raised shares of Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th. StockNews.com assumed coverage on Can-Fite BioPharma in a report on Friday, July 19th. They issued a “hold” rating on the stock.

Can-Fite BioPharma Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.